REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

Ascletis Pharma Inc. (Hong Kong SAR, China)

Main Activities: Research and Development in Biotechnology (except Nanobiotechnology)
Full name: Ascletis Pharma Inc. Profile Updated: March 15, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Chinese Download a sample report

Ascletis Pharma Inc. is a biotechnology company that focuses on three therapeutic areas: anti-viral, cancer and fatty liver disease. It was founded in 2013 and is headquartered in Hangzhou City, China.

Headquarters
12/F, Building D, 198 Qidi Road Hipark, Xiaoshan District
Hangzhou; Zhejiang;

Contact Details: Purchase the Ascletis Pharma Inc. report to view the information.

Website: http://www.ascletis.com

Basic Information
Total Employees:
Purchase the Ascletis Pharma Inc. report to view the information.
Outstanding Shares:
Purchase the Ascletis Pharma Inc. report to view the information.
Registered Capital:
Purchase the Ascletis Pharma Inc. report to view the information.
Financial Auditors:
Purchase the Ascletis Pharma Inc. report to view the information.
Incorporation Date:
2014
Key Executives
Purchase this report to view the information.
Chairman
Purchase this report to view the information.
Vice President
Purchase this report to view the information.
Outside Director
Purchase this report to view the information.
Outside Director
Purchase this report to view the information.
Outside Director
Ownership Details
Purchase this report to view the information.
5.89%
Purchase this report to view the information.
4.62%
Purchase this report to view the information.
2.33%
Subsidiaries
Ap11 Limited (United Kingdom)
100%
Powertree Investment (Bvi) Ltd. (United Kingdom)
100%
Company Performance
Financial values in the chart are available after Ascletis Pharma Inc. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency CNY. Absolute financial data is included in the purchased report.
Net sales revenue
4.63%▲
Total operating revenue
-20.47%▼
Operating profit (EBIT)
10.23%▲
EBITDA
-16.22%▼
Net Profit (Loss) for the Period
54.04%▲
Total assets
-6.25%▼
Total equity
-7.79%▼
Operating Profit Margin (ROS)
76.64%▲
Net Profit Margin
326.37%▲
Return on Equity (ROE)
6.22%▲
Debt to Equity Ratio
0.19%▲
Quick Ratio
-6.79%▼
Cash Ratio
-20.49%▼

Similar companies

Keymed Biosciences Inc. (Hong Kong) (康诺亚生物医药科技有限公司 (香港))
 
WuXi AppTec Co., Ltd. (Shanghai) (无锡药明康德新药开发股份有限公司 (上海))
BeiGene, Limited
 
Shanghai Junshi Biosciences Company Limited
Shandong Boan Biotechnology Company Limited
 
Ascentage Pharma Group International (Hong Kong) (亚盛医药集团-B (香港))
JW Cayman Therapeutics Company Limited
 
Brii Biosciences Limited
Hua Medicine (Shanghai) (华领医药 (上海))
 
Abbisko Cayman Limited

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo